RxDoctor Payments Data

Michelle Cancel, MD

Pulmonary Disease · Nashville, TNNPI 1093245581

Payments from drug & device makers

$3,632in general payments, 2019–2025

Across 71 payments — averaging $51.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$2K
  • Olympus Corporation Of The Americas$967
  • Johnson & Johnson$261
  • Medtronic$160
  • Astellas Pharma US Inc$118
  • Actelion Pharmaceuticals US, Inc.$103
  • plus $442 from 14 others

What the payments were for

  • Travel & lodging$91425%
  • Food & beverage$1,21834%
  • Education$1,50041%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,632 in reported general payments places this provider in the 45th percentile of 339 pulmonary disease providers in Tennessee.

See all pulmonary disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$46,080
Medicare patients
399
Services billed
761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan11$133,857
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$69,876
Ambrisentan14$26,946
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr38$22,164
Incruse ElliptaUmeclidinium Bromide19$8,132
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate18$6,927
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,997
Albuterol Sulfate HfaAlbuterol Sulfate36$1,541
Ventolin HfaAlbuterol Sulfate13$1,039
Montelukast Sodium16$196
Azithromycin24$138
Fluticasone Propionate17$107
Prednisone18$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit$103$133,85711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 339 pulmonary disease providers in Tennessee.

Other pulmonary disease in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →